• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

克隆分析表明,复发性星形细胞瘤、少突星形细胞瘤和少突胶质细胞瘤中存在 IDH1 突变,这是常见的肿瘤起始事件。

Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event.

机构信息

Clinical Cooperation Unit Neuropathology, German Cancer Center (DKFZ), Heidelberg, Germany.

出版信息

PLoS One. 2012;7(7):e41298. doi: 10.1371/journal.pone.0041298. Epub 2012 Jul 23.

DOI:10.1371/journal.pone.0041298
PMID:22844452
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3402513/
Abstract

BACKGROUND

To investigate the dynamics of inter- and intratumoral molecular alterations during tumor progression in recurrent gliomas.

METHODOLOGY/PRINCIPAL FINDINGS: To address intertumoral heterogeneity we investigated non-microdissected tumor tissue of 106 gliomas representing 51 recurrent tumors. To address intratumoral heterogeneity a set of 16 gliomas representing 7 tumor pairs with at least one recurrence, and 4 single mixed gliomas were investigated by microdissection of distinct oligodendroglial and astrocytic tumor components. All tumors and tumor components were analyzed for allelic loss of 1p/19q (LOH 1p/19q), for TP53- mutations and for R132 mutations in the IDH1 gene. The investigation of non-microdissected tumor tissue revealed clonality in 75% (38/51). Aberrant molecular alterations upon recurrence were detected in 25% (13/51). 64% (9/14) of these were novel and associated with tumor progression. Loss of previously detected alterations was observed in 36% (5/14). One tumor pair (1/14; 7%) was significant for both. Intratumoral clonality was detected in 57% (4/7) of the microdissected tumor pairs and in 75% (3/4) of single microdissected tumors. 43% (3/7) of tumor pairs and one single tumor (25%) revealed intratumoral heterogeneity. While intratumoral heterogeneity affected both the TP53- mutational status and the LOH1p/19q status, all tumors with intratumoral heterogeneity shared the R132 IDH1- mutation as a common feature in both their microdissected components.

CONCLUSIONS/SIGNIFICANCE: The majority of recurrent gliomas are of monoclonal origin. However, the detection of divertive tumor cell clones in morphological distinct tumor components sharing IDH1- mutations as early event may provide insight into the tumorigenesis of true mixed gliomas.

摘要

背景

为了研究复发性神经胶质瘤肿瘤进展过程中肿瘤内和肿瘤间分子改变的动态变化。

方法/主要发现:为了研究肿瘤间异质性,我们研究了 106 例代表 51 例复发性肿瘤的非微切割肿瘤组织。为了研究肿瘤内异质性,我们通过微切割不同的少突胶质细胞和星形胶质细胞瘤成分,研究了一组 16 例代表 7 对具有至少一次复发的肿瘤对和 4 例单独的混合神经胶质瘤。所有肿瘤和肿瘤成分均进行 1p/19q 等位基因缺失(LOH1p/19q)、TP53 突变和 IDH1 基因 R132 突变的分析。非微切割肿瘤组织的研究显示 75%(38/51)的克隆性。在 25%(13/51)的复发性肿瘤中发现了异常分子改变。其中 64%(9/14)是新的,与肿瘤进展有关。在 36%(5/14)的情况下,先前检测到的改变丢失。一个肿瘤对(1/14;7%)两者都显著。在微切割肿瘤对中,57%(4/7)检测到肿瘤内克隆性,在单个微切割肿瘤中,75%(3/4)检测到肿瘤内克隆性。肿瘤对的 43%(3/7)和单个肿瘤(25%)显示出肿瘤内异质性。虽然肿瘤内异质性影响 TP53 突变状态和 LOH1p/19q 状态,但所有具有肿瘤内异质性的肿瘤都共享 R132 IDH1 突变作为其微切割成分的共同特征。

结论/意义:大多数复发性神经胶质瘤为单克隆起源。然而,在形态学上明显不同的肿瘤成分中检测到具有 IDH1 突变的分化肿瘤细胞克隆作为早期事件,可能为真正的混合神经胶质瘤的肿瘤发生提供线索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ad/3402513/9ab028ca4b87/pone.0041298.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ad/3402513/79fa9fca207b/pone.0041298.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ad/3402513/93d4485e390c/pone.0041298.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ad/3402513/77f35604e17a/pone.0041298.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ad/3402513/9ab028ca4b87/pone.0041298.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ad/3402513/79fa9fca207b/pone.0041298.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ad/3402513/93d4485e390c/pone.0041298.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ad/3402513/77f35604e17a/pone.0041298.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ad/3402513/9ab028ca4b87/pone.0041298.g004.jpg

相似文献

1
Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event.克隆分析表明,复发性星形细胞瘤、少突星形细胞瘤和少突胶质细胞瘤中存在 IDH1 突变,这是常见的肿瘤起始事件。
PLoS One. 2012;7(7):e41298. doi: 10.1371/journal.pone.0041298. Epub 2012 Jul 23.
2
Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report.形态学、遗传学和空间上混合的星形细胞瘤和少突胶质细胞瘤;1p/19q共缺失和CDKN2A缺失的时间顺序获得:一例报告
Brain Tumor Pathol. 2023 Jan;40(1):26-34. doi: 10.1007/s10014-022-00448-z. Epub 2022 Dec 26.
3
Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.中国单机构 77 例间变性少突胶质细胞瘤分子预后因素及其相关性研究
Neuro Oncol. 2012 Jan;14(1):109-16. doi: 10.1093/neuonc/nor185. Epub 2011 Oct 27.
4
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.胶质瘤中1p36和19q13的等位基因缺失:与组织学分类的相关性、1p36上150kb最小缺失区域的定义以及CAMTA1作为候选肿瘤抑制基因的评估
Clin Cancer Res. 2005 Feb 1;11(3):1119-28.
5
Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.新型分子立体定向活检程序揭示了世界卫生组织II级胶质瘤中1p/19q杂合性缺失和TP53突变的肿瘤内同质性。
J Neuropathol Exp Neurol. 2009 Nov;68(11):1219-28. doi: 10.1097/NEN.0b013e3181bee1f1.
6
Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.91例星形细胞瘤和少突胶质细胞瘤中1p、19q、10q、TP53、EGFR、CDK4和CDKN2A的组织学与分子遗传学分析的相关性
Clin Cancer Res. 2002 Jan;8(1):196-201.
7
Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.原发和复发性寡树突胶质细胞瘤获得性 1p/19q 不平衡缺失和 TP53 突变的比较分子分析:1 例报告。
Acta Neurochir (Wien). 2020 Dec;162(12):3019-3024. doi: 10.1007/s00701-020-04514-3. Epub 2020 Aug 12.
8
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.对于未接受早期放疗的患者,异柠檬酸脱氢酶1(IDH1)突变对弥漫性星形细胞瘤具有预后价值,但对低级别少突胶质细胞瘤则不然。
J Neurooncol. 2015 Sep;124(3):493-500. doi: 10.1007/s11060-015-1863-5. Epub 2015 Aug 5.
9
Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.并非所有1p/19q未缺失的少突胶质细胞瘤都是星形细胞性的。
Oncotarget. 2016 Oct 4;7(40):64615-64630. doi: 10.18632/oncotarget.11378.
10
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.临床多重外显子组测序可区分成人少突胶质细胞瘤与星形细胞瘤及混合谱系胶质瘤。
Oncotarget. 2014 Sep 30;5(18):8083-92. doi: 10.18632/oncotarget.2342.

引用本文的文献

1
ATRX loss in adult gliomas lacking H3 alterations or IDH mutations, an exceptional situation for exceptional diagnoses: the experience of Sainte-Anne hospital.在缺乏H3改变或异柠檬酸脱氢酶(IDH)突变的成人胶质瘤中ATRX缺失:特殊诊断的特殊情况——圣安妮医院的经验
Acta Neuropathol Commun. 2025 Jun 13;13(1):131. doi: 10.1186/s40478-025-02044-6.
2
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.伏立西尼在异柠檬酸脱氢酶突变型胶质瘤治疗中的作用。
Neuro Oncol. 2024 Dec 25. doi: 10.1093/neuonc/noae259.
3
Dual phenotypes in recurrent astrocytoma, IDH-mutant; coexistence of IDH-mutant and IDH-wildtype components: a case report with genetic and epigenetic analysis.

本文引用的文献

1
Addressing diffuse glioma as a systemic brain disease with single-cell analysis.通过单细胞分析将弥漫性胶质瘤作为一种全身性脑部疾病来研究。
Arch Neurol. 2012 Apr;69(4):523-6. doi: 10.1001/archneurol.2011.2910. Epub 2011 Dec 12.
2
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.癌症相关的 IDH1 突变会产生 2-羟基戊二酸。
Nature. 2009 Dec 10;462(7274):739-44. doi: 10.1038/nature08617.
3
Monoclonal antibody specific for IDH1 R132H mutation.针对 IDH1 R132H 突变的单克隆抗体。
复发性星形细胞瘤中的双重表型,IDH 突变型;IDH 突变型和 IDH 野生型成分共存:一例伴有遗传和表观遗传分析的病例报告。
Acta Neuropathol Commun. 2024 Oct 26;12(1):169. doi: 10.1186/s40478-024-01879-9.
4
IDH inhibition in gliomas: from preclinical models to clinical trials.IDH 抑制剂在脑胶质瘤中的应用:从临床前模型到临床试验。
Nat Rev Neurol. 2024 Jul;20(7):395-407. doi: 10.1038/s41582-024-00967-7. Epub 2024 May 17.
5
Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.分子标志物检测在弥漫性胶质瘤诊断中的应用
Arch Pathol Lab Med. 2022 May 1;146(5):547-574. doi: 10.5858/arpa.2021-0295-CP.
6
Synchronous supratentorial and infratentorial oligodendrogliomas with incongruous IDH1 mutations, a case report.幕上和幕下同时发生的少突胶质细胞瘤伴不一致的 IDH1 突变:1 例报告。
Acta Neuropathol Commun. 2021 Sep 29;9(1):160. doi: 10.1186/s40478-021-01265-9.
7
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.胶质瘤中的基因改变重塑肿瘤免疫微环境并影响免疫介导的治疗。
Front Oncol. 2021 Jun 8;11:631037. doi: 10.3389/fonc.2021.631037. eCollection 2021.
8
Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma.染色体缺陷追踪少突胶质细胞瘤中的肿瘤亚群并在进展过程中发生变化。
Converg Sci Phys Oncol. 2015 Sep;1(1). doi: 10.1088/2057-1739/1/1/015001. Epub 2015 Jun 16.
9
Association between mutations and brain glioma grade.突变与脑胶质瘤分级之间的关联。
Oncol Lett. 2018 Oct;16(4):5405-5409. doi: 10.3892/ol.2018.9317. Epub 2018 Aug 17.
10
Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.基于体素的基因组学图谱分析肿瘤位置与胶质瘤患者关键分子改变的关系。
Neuro Oncol. 2018 Oct 9;20(11):1517-1524. doi: 10.1093/neuonc/noy134.
Acta Neuropathol. 2009 Nov;118(5):599-601. doi: 10.1007/s00401-009-0595-z. Epub 2009 Oct 2.
4
Genetic alterations and signaling pathways in the evolution of gliomas.胶质瘤演进过程中的遗传改变和信号通路。
Cancer Sci. 2009 Dec;100(12):2235-41. doi: 10.1111/j.1349-7006.2009.01308.x. Epub 2009 Aug 6.
5
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.非小细胞肺癌中表皮生长因子受体通路依赖性获得性表皮生长因子受体酪氨酸激酶抑制剂耐药。
Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039.
6
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.MSH6突变在替莫唑胺治疗期间出现在胶质母细胞瘤中,并介导替莫唑胺耐药。
Clin Cancer Res. 2009 Jul 15;15(14):4622-9. doi: 10.1158/1078-0432.CCR-08-3012. Epub 2009 Jul 7.
7
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.人胶质母细胞瘤中MSH6失活与新出现的替莫唑胺耐药性
Clin Neurosurg. 2008;55:165-71.
8
IDH1 and IDH2 mutations in gliomas.胶质瘤中的异柠檬酸脱氢酶1(IDH1)和异柠檬酸脱氢酶2(IDH2)突变
N Engl J Med. 2009 Feb 19;360(8):765-73. doi: 10.1056/NEJMoa0808710.
9
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.位于第132位残基的异柠檬酸脱氢酶1(IDH1)突变(IDH1(R132))在高级别胶质瘤中频繁出现,但在其他实体瘤中则不然。
Hum Mutat. 2009 Jan;30(1):7-11. doi: 10.1002/humu.20937.
10
Analysis of the IDH1 codon 132 mutation in brain tumors.脑肿瘤中异柠檬酸脱氢酶1(IDH1)第132位密码子突变的分析。
Acta Neuropathol. 2008 Dec;116(6):597-602. doi: 10.1007/s00401-008-0455-2. Epub 2008 Nov 5.